Mercadal Lucile, Montcel Sophie Tézenas du, Nochy Dominique, Queffeulou Guillaume, Piette Jean-Charles, Isnard-Bagnis Corinne, Martinez Frank
Nephrology Department, Pitié Salpêtrière Hospital, Paris, France.
Nephrol Dial Transplant. 2002 Oct;17(10):1771-8. doi: 10.1093/ndt/17.10.1771.
This study was designed to review the prognosis and the predictors of renal outcome in patients with membranous lupus nephropathy (MLN) with no or mild mesangial proliferation.
The medical records of patients (n=66) with biopsy-proven MLN, WHO class VA, and class VB without any past history of proliferative lupus nephropathy (PLN) were reviewed retrospectively.
The mean follow-up was 6.9+/-0.2 years and renal survival at 5 and 10 years was 97+/-2 and 88+/-6%. Twenty-nine patients underwent a second renal biopsy during follow-up. Fourteen of these patients (21%) had lesions of PLN. Among them, four reached end-stage renal disease (ESRD) despite immunosuppressive treatment. The probability of a transition from MLN to PLN at 10 years was 35+/-8%. Two other patients reached ESRD but did not have repeat renal biopsies and two had biopsy-proven progression to fibrosis. Independent risk factors associated with the doubling of creatinine were transition into PLN and the occurrence of a thrombosis during follow-up. The only predictor of ESRD was the haemoglobin level. PLN was not a predictor of ESRD but the efficient treatment of this form of lupus nephritis prevented that outcome.
With a long follow-up, our study noted a high frequency of transition into PLN in a large cohort of patients with MLN. Steroid usage was not predictive of outcome and did not affect renal survival, a result that must be qualified in light of the highly variable duration of treatments with steroids. The early screening and treatment of PLN is the main benefit of the close follow-up of patients with MLN. Progression to ESRD with only fibrosis remains a rare event.
本研究旨在回顾无或轻度系膜增生的膜性狼疮性肾炎(MLN)患者的预后及肾脏结局预测因素。
回顾性分析66例经活检证实为WHO V A级和V B级MLN且无增殖性狼疮性肾炎(PLN)既往史患者的病历。
平均随访时间为6.9±0.2年,5年和10年肾脏生存率分别为97±2%和88±6%。29例患者在随访期间接受了第二次肾脏活检。其中14例患者(21%)出现PLN病变。尽管进行了免疫抑制治疗,仍有4例患者进展至终末期肾病(ESRD)。10年时从MLN转变为PLN的概率为35±8%。另外2例患者进展至ESRD但未进行重复肾脏活检,2例经活检证实进展为纤维化。与肌酐翻倍相关的独立危险因素是转变为PLN以及随访期间发生血栓形成。ESRD的唯一预测因素是血红蛋白水平。PLN不是ESRD的预测因素,但有效治疗这种形式的狼疮性肾炎可预防该结局。
经过长期随访,我们的研究发现大量MLN患者转变为PLN的频率较高。类固醇使用不能预测结局且不影响肾脏生存率,鉴于类固醇治疗持续时间高度可变,这一结果需进一步评估。对MLN患者密切随访的主要益处在于早期筛查和治疗PLN。仅进展为纤维化的ESRD仍然是罕见事件。